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IN THE UNITE!) STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA

STATE OF MARYLAND, et a!
by Attorney General J. Joseph Curran, Jr.
200 St. Paul Place
Baltimore, Maryland 21202
Civ. No. 1:04CV01389 (RMC)
Plaintiffs,
V;

-

PERRIGO COMPANY, etal.
515 Eastern Avenue,
- . Allegan, M l 49010
Defendants.

FINAL ORDER AND STIPULATED PERMANENT IN JUNCTION
W HEREAS Plaintiffs, the States and Commonwealths of Maryland, Colorado, Ohio,
Florida, Michigan, Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Delaware,
District o f Columbia, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana,
Maine, Massachusetts, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey,
New Mexico, New York, North Dakota, Northern Mariana Islands, Oklahoma, Oregon,
Pennsylvania, Puerto RicO, Rhode Island, South Carolina, South Dakota, Tennessee, Texas,
Utah, Vermont, Virgin Islands, Virginia, Washington, West Virginia, Wisconsin and Wyoming
(^Plaintiff States” or “States”), filed thedr Complaint oh August 17,2004 pursuant to!Section 1 of
the Sheridan Act, 15 U.S.C. § 1 and Section 16 o f the Clayton Act, 15 U.S.C. § 26, and 28

..

U.S.C. §§ 1331,1337, and seeking civil penalties, injunctive and other equitable relief for
violations o f state antitrust, consumer protection and/oi unfair competition Statutes and related.
state laws;
AND WHEREAS, iii conjunction with the filing o f this Final Order and Stipulated
Permanent Injunction (“Final O rdef’), Plaintiff States and Defendant Perrigo Company, by their
respective attorneys, have Stipulated and agreed to entry by the Court o f this Final Order without
trial or adjudication o f any issue o f &ct or law;
AND W HEREAS, this Final Order is entered for settlement purposes only and does not
constitute any evidence against, or an. admission o f liability or any issue o f feet or law, Other than
jurisdictional, by Defendant Perrigo Company;
AND W HEREASi defendant Pemgo Company agrees to be bound by the provisions of
this Final Order pending its approval by the Court;
AND W HEREAS, Défendant Perrigo Company has rescinded the agreement challenged in
the Complaint and tins Final Order requires Defendant Perrigo Company to refrain èom entering
into similar agreements in thé future to remedy the competition lost as alleged in the! Complaint;
AND W HEREAS, another aspect o f this Final Order is the payment by Defendant Perrigo
Company o f 1) $333,333.50 to the Plaintiff States and o f 2) $666,666.50 to the Mew York M ilk
A ntitrust Litigation Fund Account, rèpiesenting equitable relief and/or settlement payments in
lieu o f dyirpenaltieS;
A M ) W HEREAS, Defendant Perrigo Company will pay $248,863.25 to Liaison Counsel
for the Plaintiff States in attorneys’ fees, and costs of investigation;

AND W HEREAS, Defendant P'erngo Company has represented to the Plaintiff States that
the relief required below can and will be made and that Defendant Pefrigo Company will later
raise no claim o f hardship or difficulty as grounds for asking the Court to modify any o f the
terms o f the relief contained below;
AND WHEREAS, Defendant Perrigo Company, without admitting that'it has violated any
provision o f fédéral or state law, agrees to the entry o f this Final Order;
NOW THEREFORE, before any testimony is taken, without trial or adjudication o f any
issue of &ct or law, and upon consènt o f the parties, it is
ORDERED, AD JUDGED AND DECREED THAT:

l Jurisdiction and Venue
A. This Court has jurisdiction over Defendant Perrigo Company (''Perrigo”) and the subject
matter o f this action. Perrigo’s activities, including the acts and practices alleged in Plaintiff
States’ Complaint, are in or affecting commerce, as “commerce” is defined in 15 U.S.C. §
44..
B. Venue is proper in this Court under Section 12 o f the Clayton Act, 15 U.S.C. § 22 and 28
U .S.C.§§ 1391(b) and (c).
C. The Complaint states a claim upon which relief may be granted against Perrigo pursuant to
the statutes cited therein,
D. This case is a proper1case for the issuance o f a permanent injunction. The Plaintiff States
have authority pursuant to Section 16 o f the Clayton Act, 15 U.S.C. § 26 and pursuant to
state statutes cited in thé Complaint to seek the relief requested.
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E. Perrigo waives all rights to appeal or otherwise challenge or contest the validity o f this Final
Order.

H. Definitions
IT ÌS F U ÏttÎÎÉ R ORDERED, ADJUDGED AND DECREED TEAT, as used in this
Final Order:
A.

“Perrigo” means.Perrigo Company and its officers, directors, employees, agents and
representatives, successors and assigns; subsidiaries, divisions, groups and affiliates
controlled by Perrigo Company; and the officers, directors, employees, agents and
representatives, successore and assigns of each.

B> ■ “180-day Exclusivity Period” means the six month market exclusivity period provided to
the First Filer o f mi ANDA under 21 U.S.Ç. § 355(j), et seq.

Ù

“Agreement” means anything that would constitute a contract, combination, o r conspiracy
vdthin the meaning o f Section 1 o f the Sherman Act, 15TJ.S.C. § 1, regardless‘o f whether
such contract, combination, or conspiracy is in restraint o f trade.

t).

“Agreement Subject to Notification” means an Agreement in or affecting Commerce in
:

'

.

,

1

‘

1

*.

which a party to thè Agreement agrees to refrain from, or to limit for any period o f time,
■

.

1

’

.

i

’

the research, development, manufacture, marketing, distribution or sale o f an ANDA Drug
Product that it Controls and that is O f The Same Kind as another ANDA Drug Product
Controlled by another party to the Agreement.
È.

“AND A” means an Abbreviated New Drug Application, as defined under
21 U.S.C.§ 3$5(j), et sëq.

•
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F.

“ANDA Drag Iproduct” means a finished Dosage Foim that ( 1) contains a drag substance
generally» but not necessarily in association with one or more other ingredients as defined in

21 C.F.R. § 314.3(b), and (2) is the subject o f an ANDA filed with or approved by the
FDA.
G.

“Commerce” has the sanie definition as it has in 15 U.S.C. § 44,

H.

“Commission” means the Federal Trade Commission,

I.

“Control” .means» in connection With an ANDA Drug Product, to (1) exclusively distribute
an ANDÂ Drug Product, (2) have the rights to an ANDA Drug Product accruing from the
FDA’s approval o f an ANDA, or (3) be in position to obtain such rights if the FDA were to
approve an ANDA thât has been filed with the FDA.

J.

“Date o f the Agreement” means the date the Agreement is executed Or otherwise goes into
effect.

K.

“Dosage Form” means a category o f drug delivery, including, but not limited to; the
following categories; (a) tablets, (b) capsules, (c) liquids administered orally, (d) liquids
administered intravenously Ox subcutaneously, (e) nasal spays, (f) transdermal patches, and
(g) suppositories.

D

:

“Enter into” means join, participate in, implement, adhere to, maintain, organize, enforce, or
facilitate..

''

M.

“First Commercial Marketing” has the same meaning it has in 21 C.F.R. §314.107(c)(4).

N,

“First Filer of ah ANDA” means the party whom the FDA determines is entitled to or
eligible for, under 21 U.S.C. § 355(j), et seq.s a right to a 180-day Exclusivity Period that
has not yèt expired.
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Ó.

“FDA” means the United States Food and Drug Administration.

P.

“Liaison Counsel for the Plaintiff States” means counsel for the States o f Maryland,
Colorado, Ohio, Florida and Michigan.

Q.

“Marketing Type” means the following two categories: over-the-counter (“OTC”) and
prescription (“Rx”), For purposes o f this Final Order, an ANDA Drug Product is in the OTC
category if its ANDA references an NDA for an OTC drug product arid is in the Rx category
if its ANDA references an NDA for an Rx drug product.

R.

“NDA” means a New Drug Application, as defined under 21 U.S.C. § 355(b).

S.

“O fThe Same Kind” means to 1) have the same Dosage Form, 2) contain the same, and
only the saíne active pharmaceutical ingredients), and 3) he o f the same Marketing Type.

T.

“Patent ínMtígemeht Claim” means any written allegation o f patent infringement, whether
or not included in a complaint tiled with a court o f law.

U:

“Person** means both natural persons and artificial persons, including, but not limited to,
corporations, unincorporated entities, and governments.

V.

“Plaintiff States” means the States and Commonwealths o f Maryland, Colorado, Ohio,
Florida, Michigan, Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Delaware,
District o f Columbia, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana,
Maine, Massachusetts, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New
Jersey, New Mexico, New York, North Dakota, Northern Mariana Islands, Oklahoma,
Oregon, Pennsylvania, Puerto. Rico, Rhode Island, South Carolina, South Dakota,
Tennessee, Texas, Utah, Vermont, Virgin Islands, Virginia, Washington, W est Virginia,
Wisconsin, and Wyoming.
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111.

M onetary Relief

IT IS W R T H É R ORDERED, ADJUDGED AND DECREED THAT, not 'later than
; ' three (3) day’s after entry o f this Final Order, Penigo shall pay 1) the Sum o f $333,333.50 to the
Plaintiff States and, 2) the sum o f $666,666.50 to the New York Milk Antitrust Litigation Fund
Account (“Milk Fund Account”) under the following teams and conditions:
A,

Thè payment to thè Plaintiff States must be made by wire transfer, certified check or other
guaranteed funds made payable to and delivered as directed by the Plaintiff States. Feirigo
shall bava Or retain nò dominion, control or title to the monies transferred to òr at the

;

direction o f the Plaintiff States, and said monies shall be used at the sole discretion of
thè Attorney Hénèral in each Plaintiff State and according to the terms of this Final Order.
The Attorney General in each Plaintiff State may use these funds consistently with
his/her state lawsTor any o f the following purposes: 1) payment o f investigative1fees and .
■ costs; 2) antitrust òr Consumer protection law enforcement; 3) deposit into a state antitrust or
Consumer protection revolving fund; or 4) use in accordance with state law.1 Ail funds paid
to thè Plaintiff States or to the Liaison Counsel for the Plaintiff States pursuant to this Final'
Órdér shall be deposited into funds administered by the Plaintiff States Or their escrow agent.

' 'Si

The payment to the M ilk Fund Account must be made by wire transfer, certified* check or
Other guaranteed funds made payable to the Milk Rind Account and delivered as directed by
the Plaintiff States. Upon entry of this Order, Perrigo relinquishes all dominion, Control and
title to the monies transferred to the Milk Fund Account and agrees that said monies shall

l!With respect to the State o f Colorado, its apportionment shall be used first for
reimbursement o f Colorado’s actual costs and attorneys fees and second, to be held in trust by the
Attorney General for future consumer education, consumer fraud or antitrust enforcement efforts.

' V ,

.

.

constitute a contribution to the M ilk Fund Account subject to the Amended Order
Distributing Residue of thé Parens Patriae Settlement Fund, New York v. Dairylea
■Cooperative Inc., ¡81 Civ. 1891 (S.D.N.Y. June 22,1989).
C.

Peirigo shall haVe no right to challenge the Plaintiff States’ choice o f remedies under
Paragraph III o f this Final Order. Perrigo shall .have no right to contest the manner in
which tile funds are utilized.

D. ■ Perrigo Warrants that, as o f the date o f this Final Order, neither it nor any o f its affiliates, is
insolvent, nor will any payment to the Plaintiff States and the Milk Fund Account render it
or any of its affiliates insolvent, within the meaning o f and/or for the purposes o f the United
States Bankruptcy Code. If a case is commenced with respect to Perrigo or any o f its
affiliates, under Title 11 o f the United States Code (Bankruptcy), or a trustee, receiver or
■
\
conservator is appointed under any similar law, and in the event o f the entry o f â final order
o f a cbUft Of Competent jurisdiction determining the payment of the principal amount o f the
payment to thé Plaintiff States or the Milk Fund Accpünt, and any accrued interest, or any
portion thereof, by or on behalf o f Perrigo or any affiliate o f Peirigo, to be a preference,
voidable transfer, fraudulent transfer Or similar transaction, and if pursuant to an“order o f a ■
court o f competent jurisdiction monies paid by Perrigo or any o f its affiliates, to’the Plaintiff
States or to thé M ilk Fund Account pursuant to this Final Order either not delivered or are
rëtürned to Perrigo or any o f its affiliates, or the trustee, receiver, or conservator appointed
by a court in any bankruptcy proceeding With respect to Perrigo or any o f its affiliates, then
this Final Order shall be subject to termination and cancellation. Such termination and

s

p-

cancellation will b¿ the sole and exclusive remedy o f the Plaintiff States for breach Of this
warranty.
E .. In accordance with 31 tLS.C. § 7701, Perrigo is hereby required, unless it has done so
already, to furbish to the Plaintiff States its taxpayer identification number, which shall be
used for collecting and reporting on any delinquent amount arising out o f Perrigo’s
relationship with the government.

IV. Prohibited Agreements

'

IT IS FARTHER ORDERED, ADJUDGED AND DECREED THAT Perrigo is enjoined
’ frOim Entering mto, or attempting to Enter into, directly or indirectly, or through any Corporate or
other device, any Agreement in or affecting Commerce with any other Person in which:
A:

a party to the Agreement agrees to refrain from, or to limit, for ariy period o f time, the
■research, development, manufacture, marketing, distribution or sale o f an ANDA Drug
Product that it Controls and that is O f The Same Kind as another ANDA Drug Product
‘
•
■=_
Controlled by another party to the Agreement, and

B.

’ .-

L

a party to the Agreement is1the First Filer o f an ANDA with respect to:
(1) any ANDA Drug Product that is the subject o f such Agreement, or

1

(2) any ANDA Drug Product that is O f The Same Kind as any ANDA Drug Product that is a

j

subject of such Agreement.

,
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p tó v n b f ^

for purposes of Paragraph IV only, an ANDA Drug Product

shall not include an ANDA withdrawn from the FDA mote than six (6) months prior to the b ate o f
the Agreement
PROVIDED ÍTJRTÍEÉR THAT nothing in Paragraph IV shall prohibit the First Filer o f an
ANDA from agreeing to'refrain from marketing, distributing, or selling the ANDA Drug Product
reféiended by súch ANDA (“the First Filer’s ANDA Drug Product”) for a period o f time lasting no .
more than 180 days after the Pirst Commercial Marketing o f any ANDA Drug Product O f th e
Same Kind as the First Filer’s ANDA Drug Product if;
5(1) such First Filer ó f án ANDA also agrees to (a) abandon, waive, selectively waive or relinquish
its Í 80-day Exclusivity Period under siich ANDA or (b) grant to another party to die
Agréementthé right td exclusively distribute such ANDA Drug Product for a period o f time
not to exceed the 180-day Exclusivity Period under such ANDA, and
(2) Perrigo notifies the Plaintiff States of such Agreement in accordance with Paragraph V of this
Final Order. .

' .

PROVIDED FURTHER THAT nothing in Paragraph IV shall prohibit the resolution o f a Patent
infringement Claim in which any party to an Agreement resolving such Patent Infringement Claim
agrees tó refrain from, dr to limit, for any period o f time prior to the expiration o f the patent that is
the basis fof the Patent Infringement Claim, such parly’s research, development, manufacturing,
■marketing, distribution, ór Salé o f an ANDA Drug Product that is the subject o f such Patent.

; frifringement Claim if:
(1) the amount received by súch party (“Receiving Party”) has a value o f no moré than; two million
dollars ($2,000,000),

|
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(2) thè tótal àmóutif givëh tò Receiving Parties by each party to the Agreement resolving such
Patent Infringement Claim (“Paying Party’*) has a value o f no more than thè Paying Party* s
expected future litigation costs to resolve such Patent Infringement Claim, and
(3) Perrigo notifies tile Plaintiff States of such settlement in accordance with Paragraph V o f this
Final Order.
, PROVIDED IfrURTtìER THAT, nothing in Paragraph IV shall prohibit Perrigo from Entering
: into any Agreement, if such Agreement is subject to the reporting obligations of Section 7A o f the
Clayton Act, 15 U.S.C. §18a (“HSR Act”), and Perrigo submits a complete and accurate
Notification Letter (as specified in Paragraph V o f this Final Order) and a Notification and Report
Form pursuant to the HSR Act for such Agreement. Nothing in this Final Order shall be construed
; to relieve Perrigo o f ariy obligation to comply with the requirements o f the HSR Act dr any other
' law o f thè “U nited State's o f Of any Plaintiff State; and any Agreement that violates any law o f the
■United States òr Of ànÿ Plaihtiff State Will continue to be subject to separate légal action for
violation o f any such law, without regard to whether it violates this Final Òrder.

V.

Agreements Subject to Notification

IT IS FURTHER ORDERED, ADJUDGED AND DECREED THAT:
*Al

Perrigo shall notify the'*Plaintiff States o f each Agreement Subject to N otificatici that
Perrigo joins, participates in, implements, adheres to, maintains, organizes, enforces or
; facilitates at any time after the entry o f this Final Order.

■

6.

Thè notification rètjuirècl by Paragraph V.A shall bè made within thirty (30) day's after the
entry o f this Final Order or within five (5) business days after the Agreement Subject to
Notification is èxecuted or otherwise goes into effect, whichever is later.

■■■. C.

The notification required by Paragraph V.A o f this Final Order shall be in the farm o f a letter
(‘"Notification Letter”) submitted to counsel for the State o f Maryland, one o f thè Liaison
Counsel for the Plaintiff States, no more than five (5) days after executing any Agreement
covered by Paragraph IV and containing the following information:

' v:

(1) the docket number' and caption name of this Final Order;
(2) a statement that the purpose Of the Notification Letter is to give the Plaintiff States
notification o f an Agreement as required by Paragraph V this Final Order;

:

(3) identification of all parties involved in the Agreemait;
(4) identification Of all ANDA Drug Products involved in the Agreement;
(5) identification o f ail Persons (to the extent known) who have filed an ANDA '
with the FDA (including the status of such application^) for any ANDA Drug Product Of
The Same Kind as the ANDA Drug Produces) involved in the Agreement;
(6) a copy of the Agreement; and
(7) identification Of the court, and a copy o f the docket sheet, for every legal action that
involves any party tó thè Agreement and relates to any ANDA Drug Product O f The Same
iCirid as the ANDA Drug Prodtict(s) involved in the Agreement
D.

W ithin thirty (30) days o f the receipt of a written request from a Liaison Counsel* for the
Plaintiff States, Perrigo shall submit to the requesting Liaison Counsel for the Plaintiff States

:

all documents which were prepared by or for any officers) or director(s) o f Pertico for the
12

ïhupôsc of evaiUatmjfor analyzing the Agreement covered by Paragraph V.Â of ibis Final
■Order. Perrigo sbali retain such documents for the full term o f this Final Order.

VL Notice and Reporting Requirements
tT IS FURTHER O ltbE R E D , ADJUDGED AND DECREED THAT Perrigo shall:
A.

File a verified, written report With the Plaintiff States setting forth in detail the manner and
form in which it has complied and is complying with the Final Order: (1) within ninety (90)
days from the date ibis Final Order is entered, (2) annually thereafter for five (5) years on the
anniversary o f the date this Final Order is entered, and (3) at such other times as the Plaintiff
States may request by written notice.

Et.

For a period o f five (5) years from the date this Final Order is entered, maintain and make
available to Plaintiff States for inspection and copying upon reasonable notice, records
sufficient to describe in detail any action taken in connection with the activities covered by
thds' Final Order.

C.

Notify the Plaintiff States at least thirty (30) days prior to any proposed (1) dissolution of
■Perrigo, (2) acquisition, merger of consolidation o f Perrigo, or (3) any other change in
Perrigo that may affect Compliance obligations arising out o f this Final Order, including but
not limited to, assignment or the creation or dissolution o f subsidiaries.

' D.
/
\

Address each notice and report required by Paragraph VI this Final Order to:
State of Maryland
Chief, Aiítitrast División
200 St. Paul Place
Baltimore, M il 212Ó2

■

State o f Colorado
Chief, Antitrust Division
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Denver, CO 80203
State o f Ohio
Chief, Antitrust Section
15Ó E¡ Gay Street
Cohimbus, OH 43215 .
State o f Florida
Director, Antitrust Division
PL-01 th e Capitol . . .
Tallahassee, FL 32399

.

E.

State o f Michigan
Assistant in Charge
Special Litigation Division
525 W; Ottawa
" P.Ò. Box 30755
Lansing, MI 48913

;.

Waive any objection to the Plaintiff States’ sharing o f information obtained pursuant to this

<

'

'

i

Final Order With thè Federal Trade Commission and the Commission’s sharing with the
Plaintiff States information obtained pursuant to the Commission’s Final Order 'and
Stipulated Injunction resolving the Commission’s complaint against Pértigo filed on August
17,2004.

-.

VÜ. Term ination of Final O rder
IT IS FURTHER ORDERED, ADJUDGED AND DECREED THAT the Final Order
shall take effect on, and expiré ten (10) years from the date this Final Order is en tered . .
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VHI. Retention of Jurisdiction
IT IS FU R IH E R ORDERED, ADJUDGED AND DECREED THAT the Court retains
jurisdiction o f this matter for purposes of construction, modification and enforcement o f this Final
■Order* ■
DC Costs
IT IS FURTHER ORDERED, ADJUDGED AND DECREED THAT Perrigo shall pay to
Liaison Counsel for the Plaintiff States $248,863.25 in attorneys’ fees and costs o f investigating
this matter. ,

